This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.0 | Synonyms: congenital aplastic anemia, Constitutional aplastic anemia, Inherited aplastic anemia, Primary aplastic anemia
The concept of aplastic anemia began in 1888 when Paul Ehrlich first described pancytopenia and fatty marrow in a young pregnant woman. Subsequently, Vaquez and Aubertin (1904) systematically classified aplastic anemia as a bone marrow failure syndrome. The concept of 'constitutional' or 'primary' aplastic anemia took shape in the 1930s–1950s as familial occurrence and association with other congenital anomalies were recognized.
In 1927, Fanconi described a syndrome of pancytopenia with multiple congenital malformations in 3 siblings, establishing Fanconi anemia as a separate entity. Diamond-Blackfan syndrome was described by Diamond and Blackfan in 1938 as congenital pure red cell aplasia. Later, in the 1990s–2000s, telomerase gene mutations (TERC, TERT) were found to be associated with bone marrow failure syndromes related to dyskeratosis congenita.
Currently, congenital/primary aplastic anemia is used as a concept encompassing various inherited bone marrow failure syndromes, including Fanconi anemia, Diamond-Blackfan syndrome, dyskeratosis congenita, Shwachman-Diamond syndrome, and familial hypoplastic anemia. These are divided according to the type of gene defect into DNA damage repair defects, ribosome biogenesis abnormalities, and telomere maintenance abnormalities.
Congenital/primary aplastic anemia is caused by mutations in a variety of genes. Major causative genes include the FANC gene family (Fanconi anemia), RPS19 and other ribosomal protein genes (Diamond-Blackfan), telomere maintenance genes such as DKC1, TERC, and TERT (dyskeratosis congenita), and SBDS (Shwachman-Diamond syndrome).
In primary aplastic anemia, an intrinsic defect exists in the hematopoietic stem cells themselves. Mechanisms such as abnormalities of DNA repair pathways, impaired ribosome biogenesis, and telomere shortening reduce the proliferative and differentiation capacity of hematopoietic stem cells. DNA damage accumulated during repeated cell divisions induces apoptosis or premature senescence.
In some congenital aplastic anemias, in addition to the primary genetic defect, a secondary autoimmune response may accompany it and further suppress bone marrow function. In addition, because of genetic instability, the risk of secondary malignancies (myelodysplastic syndrome, acute leukemia) increases.
The inheritance pattern varies depending on the syndrome causing congenital aplastic anemia. Most follow autosomal recessive inheritance (Fanconi anemia, Shwachman-Diamond syndrome). Diamond-Blackfan syndrome mainly follows autosomal dominant inheritance, and about 40–45% are de novo mutations. An X-linked form (DKC1 gene) is observed in some cases of dyskeratosis congenita.
Fanconi anemia is caused by mutations in more than 22 FANC genes, and FANCA mutations account for about 60–65% of the total. In Diamond-Blackfan syndrome, RPS19 mutations account for about 25%, and mutations in many ribosomal genes such as RPL5, RPL11, and RPL35A have been reported. In dyskeratosis congenita, mutations in more than 10 genes are known, including DKC1 (X-linked), TERC (autosomal dominant), TERT (autosomal dominant/recessive), RTEL1, and TINF2.
Accurate genetic diagnosis is essential for assessing the risk of secondary tumors, selecting the optimal treatment method (especially the need to reduce radiation and alkylating agent conditioning), screening siblings for carrier status, and family counseling.
The overall incidence of inherited bone marrow failure syndromes, including congenital/primary aplastic anemia, is estimated at about 5–10 per 1 million births. The annual incidence of Fanconi anemia is about 1–3 per 1 million births, and that of Diamond-Blackfan syndrome is estimated at 5–10 per 1 million births.
In Korea, congenital aplastic anemia is included among rare diseases eligible for Special Copayment Reduction. The number of patients in Korea with congenital bone marrow failure syndromes such as Fanconi anemia and Diamond-Blackfan syndrome is estimated at around several hundred, and the gene mutation spectrum and clinical characteristics have been reported through single-center cohort studies in Korea. Care is provided in specialized pediatric hematology-oncology departments and hematopoietic stem cell transplantation centers.
Most congenital aplastic anemias are diagnosed in childhood. The mean age at diagnosis is 7–8 years for Fanconi anemia and from a few months after birth to within 1 year for Diamond-Blackfan syndrome. Some mild phenotypes are first diagnosed in adulthood.
In Fanconi anemia, FANC proteins play an essential role in the repair of DNA interstrand crosslinks (ICL). The FANC protein complex recognizes ICL sites and activates the ICL repair pathway through monoubiquitination of the FANCD2 protein. When this pathway is defective, ICLs accumulate in hematopoietic stem cells, increasing DNA double-strand breaks, cell death, and genetic instability.
In Diamond-Blackfan syndrome, haploinsufficiency of ribosomal protein genes causes impaired ribosome biogenesis, and free ribosomal proteins (especially RPL5, RPL11) bind to MDM2 and inhibit its p53-degrading function. As a result, p53 is stabilized, increasing cell-cycle arrest and apoptosis, which is especially prominent in erythroid precursors.
In dyskeratosis congenita, defects in telomere maintenance genes cause telomeres to shorten abnormally rapidly. Telomere shortening induces replicative senescence, exhausting the proliferative capacity of hematopoietic stem cells. This vulnerability is especially evident in hematopoietic stem cells, which divide frequently.
The main symptoms of congenital aplastic anemia are determined by the three components of pancytopenia. The main symptoms are fatigue, pallor, and dyspnea due to anemia; recurrent infections and fever due to neutropenia; and bleeding (petechiae, epistaxis, gum bleeding, menorrhagia) due to thrombocytopenia.
In Fanconi anemia, various congenital physical anomalies are present, such as skin pigmentation abnormalities (café-au-lait spots, hypopigmented spots), thumb and radial anomalies, microcephaly, renal malformations (horseshoe kidney, renal agenesis), and short stature. In Diamond-Blackfan syndrome, thumb anomalies, cleft palate, and cardiac malformations may be present.
Onset in childhood is typical, but in mild phenotypes diagnosis may be delayed until adulthood. In Fanconi anemia in particular, congenital physical anomalies are often detected first, before aplastic anemia develops.
Pallor, petechiae and bruising, mucosal bleeding, and findings of recurrent infection are common signs. In Fanconi anemia, characteristic physical anomalies such as thumb and radial malformations, pigmented skin lesions, microcephaly, short stature, and delayed sexual development are observed. Splenomegaly is absent or mild.
The complete blood count shows pancytopenia (anemia, neutropenia, thrombocytopenia). Red blood cells tend to be macrocytic, and fetal hemoglobin (HbF) levels are elevated. Bone marrow examination is characterized by decreased cellularity, fatty replacement, and morphological abnormalities of the remaining cells.
The standard test for diagnosing Fanconi anemia is chromosome fragility testing using diepoxybutane (DEB) or mitomycin C (MMC). In patients with Fanconi anemia, markedly more abnormalities such as chromosome breaks and radial configurations are observed after DEB/MMC treatment compared with normal individuals.
A standard newborn screening program for congenital aplastic anemia has not yet been established. However, children born to parents who are Fanconi anemia carriers are screened after birth with genetic testing including the DEB test. In known Fanconi anemia families, sibling carrier screening for hematopoietic stem cell transplantation of siblings is also important.
In children with unexplained pancytopenia, especially when accompanied by congenital physical anomalies, congenital aplastic anemia is suspected, and DEB testing and NGS gene panel testing are performed. Among patients diagnosed with aplastic anemia, differentiation from congenital forms when evaluating the response to immunosuppressive therapy before hematopoietic stem cell transplantation is important.
In families in which a gene mutation has been identified, prenatal genetic testing by preimplantation genetic testing (PGT-M) or chorionic villus sampling is possible.
To diagnose congenital aplastic anemia, after confirming pancytopenia on the complete blood count, hypocellular marrow (<25%) on bone marrow examination, and elevated fetal hemoglobin, special tests are performed to identify the cause. The presence or absence of associated congenital malformations on clinical findings provides diagnostic clues.
When Fanconi anemia is suspected, DEB/MMC-induced chromosome fragility testing is performed. Even if this test is negative, when clinically suspected, the test is repeated in fibroblasts or bone marrow cells to exclude mosaicism. Next-generation sequencing (NGS)-based inherited bone marrow failure syndrome panel testing is becoming established as the standard test for identifying the causative gene.
Differentiation is required from acquired aplastic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria (PNH), Diamond-Blackfan syndrome, Shwachman-Diamond syndrome, and dyskeratosis congenita. PNH clone testing (flow cytometry for GPI-deficient cells) confirms an association with acquired aplastic anemia.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for congenital aplastic anemia. An HLA-matched sibling donor (MSD) is preferred whenever possible, and if none is available, an HLA-matched unrelated donor (MUD) or haploidentical transplantation is considered. In Fanconi anemia, because of the DNA repair defect, there is hypersensitivity to alkylating agents and radiation, so the conditioning intensity must be reduced.
Androgens (danazol, oxymetholone) can stimulate hematopoiesis and improve blood counts, and are used particularly in Fanconi anemia and dyskeratosis congenita before transplantation or in patients for whom transplantation is not possible. The response rate is about 50–60%, but adverse effects such as virilization and hepatotoxicity (hepatocellular adenoma, liver cancer) require caution.
Transfusion (red blood cells, platelets), hematopoietic growth factors (G-CSF), and prevention and treatment of infection are the core of supportive care. In Fanconi anemia, the risk of secondary malignancies such as head and neck squamous cell carcinoma, gynecologic cancers, gastrointestinal cancers, and acute leukemia/MDS is markedly high, so regular surveillance endoscopy and gynecologic examinations are essential.
Hematopoietic stem cell transplantation from an HLA-matched sibling donor is reported to achieve long-term survival rates of 70–90%. Transplant outcomes vary with patient age, number of transfusions before transplantation, donor type, and reduced conditioning method.
Patients with Fanconi anemia have a tens to hundreds of times higher risk of secondary malignancies (especially head and neck squamous cell carcinoma, gynecologic cancers, gastrointestinal cancers, AML/MDS) than the general population. Even after transplantation, the risk of secondary tumors does not disappear completely, so long-term follow-up is essential.
Early diagnosis, availability of an HLA-matched donor, selection of an appropriate conditioning method, and prevention of transplant-related complications (graft-versus-host disease, infection) are the key factors determining prognosis. The quality of life of survivors depends on prevention of secondary tumors and management of endocrine and organ complications.
Genetic counseling is provided to families of patients with congenital aplastic anemia, and when a gene mutation is identified, the birth of an affected fetus can be prevented through prenatal genetic testing (CVS, amniocentesis) or preimplantation genetic testing (PGT-M). It is also used to identify siblings who are HLA-matched donors.
To prevent secondary tumors in patients with Fanconi anemia, exposure to tobacco, alcohol, and carcinogenic environmental factors is avoided, and surveillance programs such as regular head and neck endoscopy, obstetric-gynecologic examinations, and colonoscopy are followed. Human papillomavirus (HPV) vaccination is recommended for the prevention of gynecologic and head and neck cancers.
Regular multidisciplinary follow-up is required to prevent endocrine complications (growth impairment, diabetes, hypothyroidism), hepatic complications (during androgen therapy), decreased bone density, neurocognitive developmental abnormalities, and transplant-related complications (graft-versus-host disease, infertility).